SiMPore, Inc.

WEST HENRIETTA, NY · Founded 2007 · CIK 0001431967 · Biotech · Private

Freely suspended silicon nanomembrane technology for biomedical and material science applications

simpore.com →
Grants
$8.1M
17 awards
Sector median: 1
Raised
$1.0M
1 Form D · Jun 2010
196 months since last filing
Contracts
—
No federal contracts on record
Patents
24
6 granted · 18 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,000,000
Federal grantNational Science Foundation · Phase I · STTR Phase I: Development of Ultrathin Nanomembranes for Home-based Hemodialysis$225,000
Federal grantDepartment of Health and Human Services · Phase I · Enabling Nanomembrane-Based Biomolecule and Nanoparticle Separations$198,938
Federal grantDepartment of Health and Human Services · Phase I · Enabling Nanomembrane-Based Biomolecule and Nanoparticle Separations$198,938
Federal grantNational Science Foundation · Phase II · STTR Phase II: Development of Ultrathin Nanomembranes for Home-based Hemodialysis$907,724
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Microfabrication-based Biomimetic Approach for In Vitro Red Blood Cell Maturation$225,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Microfabrication based Biomimetic Approach for In Vitro Red Blood Cell Maturation$225,000
Federal grantDepartment of Health and Human Services · Phase I · Isoporous Silicon Nanomembranes for Purification of Therapeutic Viruses$225,000
Federal grantDepartment of Health and Human Services · Phase I · Isoporous Silicon Nanomembranes for Purification of Therapeutic Viruses$225,000
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · SEA-PUR: A New Platform for Improved Microplastic Contamination Surveillance$225,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · SEA-PUR: A New Platform for Improved Microplastic Contamination Surveillance$225,000
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Commercializing the µSIM: A Modular Platform for the Development and Analysis of Barrier Tissue Models$235,000
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Commercializing the µSIM:A Modular Platform for the Development and Analysis of Barrier Tissue Models$235,000
Federal grantDepartment of Health and Human Services · Phase II · Commercialization of Novel Silicon Microslit Filters for Microplastic Contamination Testing$667,570
Federal grantDepartment of Health and Human Services · Phase II · Commercializing the μSIM: A Modular Platform for the Development and Analysis of Barrier Tissue Models$893,657
Federal grantDepartment of Health and Human Services · Phase II · Commercializing the μSIM: A Modular Platform for the Development and Analysis of Barrier Tissue Models$1,694,475
Federal grantDepartment of Health and Human Services · Phase II · Commercialization of Novel Silicon Microslit Filters for Microplastic Contamination Testing$703,511
Federal grantDepartment of Health and Human Services · Phase II · Commercializing the μSIM: A Modular Platform for the Development and Analysis of Barrier Tissue Models$800,818
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3337PURE BIOSCIENCE, INC.—$29M
3338Timberlyne Therapeutics——
3339POP Biotechnologies Inc.——
3340SiMPore, Inc.—$1.0M
3341DATIRIUM LLC——
3342Stealth Biosciences, Inc——
3343SOMATOLYNK, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Mark AinDirector
  • Phillippe FauchetDirector
  • Ted FranceschiDirector
  • Thomas GaborskiDirector · Executive Officer
  • James McGrathDirector · Promoter
  • Kevin ParkerDirector
  • Richard RichmondDirector · Executive Officer · Promoter
  • Geoff RosenbergerDirector
  • Christopher StriemerExecutive Officer

Patents

USPTO · 6 granted of 24

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.